Ripretinib in Chinese Patients With Advanced GIST: a Real World Study

Status Active, not recruiting

Clinical Trial Summary

to evaluate the clinical efficacy, safety and predictive factors of ripetinib in Chinese patients with advanced GIST in the real world

Clinical Trial Description

Ripretinib has become the standard ≥ 4L treatment in advanced GIST. Given the small sample size of patients in the China bridging study of INVICTUS as well as the short marketing time of ripretinib, further exploration on the long-term efficacy and safety of ripretinib, as well as the dominant gene mutation type of ripretinib in Chinese GIST patients is required. Hence, we plan to further explore the efficacy of ripretinib, predictors of efficacy, etc. by collecting and analyzing real-world data from Chinese patients with advanced GIST recieving ripretinib. ;

Study Design

Related Conditions & MeSH terms

Gastrointestinal Stromal Tumors

Clinical Trial Details

NCT number	NCT05697107
Study type	Observational
Source	Peking University
Contact
Status	Active, not recruiting
Phase
Start date	May 20, 2021
Completion date	December 30, 2023

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05385549` - 5 Years of Adjuvant Imatinib in Patients With Gastrointestinal Stromal Tumor With a High Risk	Phase 2
Recruiting	`NCT05905887` - Rivoceranib Plus Paclitaxel in Patients With Gastrointestinal Stromal Tumor	Phase 2
Completed	`NCT01933958` - Regorafenib Post-marketing Surveillance in Japan
Recruiting	`NCT04584008` - Targeted Agent Evaluation in Digestive Cancers in China Based on Molecular Characteristics	N/A
Completed	`NCT01440959` - Dovitinib for Imatinib/Sumitinib-failed Gastrointestinal Stromal Tumors (GIST): TKI258	Phase 2
Completed	`NCT00718562` - Efficacy and Safety of AMN107 in Patients With GastroIntestinal Stromal Tumors (GIST) Who Have Failed Both Imatinib and Sunitinib	Phase 2
Completed	`NCT00385203` - The Biological Activity of Cediranib (AZD2171) in Gastro-Intestinal Stromal Tumours(GIST).	Phase 2
Completed	`NCT00137449` - Study Of SU011248 Administered On A Continuous Daily Dosing Schedule In Patients With Gastrointestinal Stromal Tumor	Phase 2
Completed	`NCT00237172` - Phase II Clinical Study of Imatinib Mesylate in Patients With Malignant Gastrointestinal Stromal Tumors (Extension Study)	Phase 2
Terminated	`NCT04409223` - Efficacy and Safety of Famitinib Versus Sunitinib in the Treatment of Advanced Gastrointestinal Stromal Tumour Patients After Failure of Imatinib	Phase 3
Active, not recruiting	`NCT03556384` - Temozolomide (TMZ) In Advanced Succinate Dehydrogenase (SDH)-Mutant/Deficient Gastrointestinal Stromal Tumor (GIST)	Phase 2
Recruiting	`NCT04106024` - Efficacy and Safety of Anlotinib in Patients With Advanced Gastrointestinal Stromal Tumor After Failure of Imatinib: a Prospective, Single Arm and Multicenter Trial	Phase 2
Completed	`NCT02171286` - The Oncopanel Pilot (TOP) Study	N/A
Completed	`NCT01114087` - Impact of the Inhibitors of Tyrosine Kinase on the Male Fertility	N/A
Recruiting	`NCT05366816` - ctDNA-Guided Sunitinib And Regorafenib Therapy for GIST	Phase 2
Recruiting	`NCT03602092` - Observational Registry Data on GIST Patients
Recruiting	`NCT05197933` - Safety of Laparoscopic Resection for Gastrointestinal Stromal Tumor on Unfavorable Anatomic Site of Stomach	N/A
Completed	`NCT02931929` - MITIGATE-NeoBOM: A Study to Evaluate 68Ga- NeoBOMB1 in Patients With Advanced TKI-treated GIST Using PET/CT	Phase 1/Phase 2
Withdrawn	`NCT05080621` - Ripretinib in Combination With Binimetinib in Patients With Gastrointestinal Stromal Tumor (GIST)	Phase 1/Phase 2
Completed	`NCT02638766` - Single Agent Regorafenib in First-line for Metastatic/Unresectable KIT/PDGFR Wild Type GIST	Phase 2